Neostigmine Methylsulfate Injection, USP Simplist (Prefilled Syringe)

Fresenius Kabi USA, LLC

Revision date : 2024-10-04

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
GHS07 GHS08
Health risk rating 5
Safety risk rating 1
Environmental risk rating 1

Note: Ingredients listed on restricted chemical lists

EC/CAS

108-95-2

Name of the chemical

Phenol

Concentration

0.45 %

EC/CAS

7732-18-5

Name of the chemical

Water, distilled, conductivity or of similar purity H2O

Concentration

N/A

General Information

Version

10/04/2024

Revision date

2024-10-04

Product name

Neostigmine Methylsulfate Injection, USP Simplist (Prefilled Syringe)

Product name

Neostigmine Methylsulfate Injection, USP Simplist (Prefilled Syringe)

Identification on the label/Trade name

Neostigmine Methylsulfate Injection, USP Simplist (Prefilled Syringe) | Manufacturer Fresenius Kabi USA LLC

Manufacturer Name

Fresenius Kabi USA, LLC

Icons in SDS

GHS07 GHS08 M004 M009 M010 M011 M013 M017 M026 M059

Company Information

company name

Fresenius Kabi USA, LLC

GHS Information

Signal word

DANGER

Hazard Codes

Hazard statements (CLP)

H317, H334, H341, H362

Hazard statements

Code

Statements

H317

May cause an allergic skin reaction

H334

May cause allergy or asthma symptoms or breathing difficulties if inhaled

H341

Suspected of causing genetic defects

H362

May cause harm to breast-fed children

Section 2

Signal word

DANGER. GHS Class Respiratory sensitisation. category 1. Germ cell mutagenicity. Category 2. Skin Sensitization. category 1. Reproductive toxicity. Effects on or via lactation.

Hazard statements

May cause allergy or asthma symptoms or breathing difficulties if inhaled. Suspected of causing genetic defects. May cause an allergic skin reaction. May cause harm to breast-fed children.

Precautionary statements

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dust/fume/gas/mist/vapours/spray. Avoid breathing dust/fume/gas/mist/vapours/spray. Avoid contact during pregnancy and while nursing. Wash hands thoroughly after handling. Do not eat, drink or smoke when using this product. Contaminated work clothing should not be allowed out of the workplace. Wear protective gloves/protective clothing/eye protection/face protection. In case of inadequate ventilation wear respiratory protection. IF ON SKIN: Wash with plenty of water. IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. IF exposed or concerned: Get medical advice/attention. Specific treatment (see ... on this label). If skin irritation or rash occurs: Get medical advice/attention. If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician. Take off contaminated clothing and wash it before reuse. Store locked up. Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations. Emergency Overview This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

Principle Routes of Exposure

Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential health effects

Eye Contact with eyes may cause irritation. Skin May cause skin irritation. Skin contact may result in allergic-type skin rash and hypersensitivity reactions. Inhalation May cause irritation of respiratory tract. May cause respiratory sensitization with asthma-like symptoms in susceptible individuals. Ingestion May cause irritation. Signs/Symptoms Adverse reactions from therapeutic doses generally are due to an exaggeration of pharmacological effects of which salivation and fasciculation are the most common. Other adverse reactions include: Bowel cramps and diarrhea. Overdosage of neostigmine methylsulfate can cause cholinergic crisis, which is characterized by increasing muscle weakness, and through involvement of the muscles of respiration, may result in death. The immediate use of atropine in cholinergic crisis is recommended; but such use, by masking signs of overdosage, can lead to inadvertent induction of cholinergic crisis. Occupational exposure has not been fully investigated. Aggravation of Pre-Existing Individuals with known hypersensitivity to the drug and individuals with peritonitis or mechanical Conditions obstruction of the intestinal or urinary tract.

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.